Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 18;25(18):10046.
doi: 10.3390/ijms251810046.

Emerging Targets in Non-Small Cell Lung Cancer

Louisa Liu  1 , Joshua Soler  2 , Karen L Reckamp  1 , Kamya Sankar  1
Affiliations
Review

Emerging Targets in Non-Small Cell Lung Cancer

Louisa Liu et al. Int J Mol Sci. .

Abstract

Lung cancer is responsible for a high burden of disease globally. Over the last two decades, the discovery of targetable oncogenic genomic alterations has revolutionized the treatment landscape for early-stage and advanced non-small cell lung cancer (NSCLC). New molecular drivers continue to emerge as promising therapeutic targets, including KRAS non-G12C, RAF/MEK, HER3, Nectin-4, folate receptor alpha, ITGB6, and PRMT5. In this review, we summarize the emerging molecular targets with a potential clinical impact in advanced NSCLC, elaborating on their clinical characteristics and specific mechanisms and molecular pathways for which targeted treatments are currently available. Additionally, we present an aggregate of ongoing clinical trials investigating the available treatment options targeting such alterations, in addition to their current recruitment status and preliminary efficacy data. These advancements may guide further research endeavors and inform future treatment strategies to improve the management of and transform outcomes for patients with advanced NSCLC.

Keywords: non-small cell lung cancer; novel combinatorial approaches; oncogene driver; targeted therapies.

PubMed Disclaimer

Conflict of interest statement

L.L. and J.S. have no conflicts of interest to disclose. K.S.: Research funding to institution: Genentech; Black Diamond; Lilly; Harpoon Therapeutics; Merck. K.R.: Consultant with honoraria to self: Amgen; AstraZeneca; Blueprint; Daiichi Sankyo; Genentech; GlaxoSmithKline; Janssen; Lilly; Mirati; Novartis; Novocure. Research funding to institution: Genentech; Blueprint; Daiichi Sankyo; Elevation Oncology; Janssen.

Figures

Figure 1
Figure 1
Depiction of the interplay of the major pathways to be discussed in this review (KRAS, BRAF/MEK, and HER3).
See this image and copyright information in PMC

References

    1. Ettinger D.S., Wood D.E., Aisner D.L., Akerley W., Bauman J.R., Bharat A., Bruno D.S., Chang J.Y., Chirieac L.R., D’Amico T.A., et al. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2022;20:497–530. doi: 10.6004/jnccn.2022.0025. - DOI - PubMed
    1. Majeed U., Manochakian R., Zhao Y., Lou Y. Targeted therapy in advanced non-small cell lung cancer: Current advances and future trends. J. Hematol. Oncol. 2021;14:108. doi: 10.1186/s13045-021-01121-2. - DOI - PMC - PubMed
    1. Olmedo M.E., Cervera R., Cabezon-Gutierrez L., Lage Y., Corral de la Fuente E., Gómez Rueda A., Mielgo-Rubio X., Trujillo J.C., Couñago F. New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2. World J. Clin. Oncol. 2022;13:276–286. doi: 10.5306/wjco.v13.i4.276. - DOI - PMC - PubMed
    1. Hong D.S., Fakih M.G., Strickler J.H., Desai J., Durm G.A., Shapiro G.I., Falchook G.S., Price T.J., Sacher A., Denlinger C.S., et al. KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors. N. Engl. J. Med. 2020;383:1207–1217. doi: 10.1056/NEJMoa1917239. - DOI - PMC - PubMed
    1. Hong D.S., DuBois S.G., Kummar S., Farago A.F., Albert C.M., Rohrberg K.S., van Tilburg C.M., Nagasubramanian R., Berlin J.D., Federman N., et al. Larotrectinib in patients with TRK fusion-positive solid tumours: A pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020;21:531–540. doi: 10.1016/S1470-2045(19)30856-3. - DOI - PMC - PubMed

MeSH terms

Substances